The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL)

被引：0
|
作者：
Abuhadra, N. [1 ]
Sun, R. [2 ]
Litton, J. K. [1 ]
Rauch, G. [3 ]
Thompson, A. M. [4 ]
Lim, B. [1 ]
Adrada, B. [3 ]
Mittendorf, E. [5 ]
Damodaran, S. [6 ]
Pitpitan, R. [3 ]
Arun, B. [7 ]
White, J. [1 ]
Ravenberg, E. [1 ]
Santiago, L. [3 ]
Sahin, A. [8 ]
Murthy, R. [6 ]
Ueno, N. T. [1 ]
Ibrahim, N. [1 ]
Moulder, S. [1 ]
Huo, L. [8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Div Diagnost Imaging, Dept Diagnost Radiol, Houston, TX 77030 USA
[4] Baylor Coll Med, Breast Surg Oncol, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Surg, 75 Francis St, Boston, MA 02115 USA
[6] MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX USA
[7] MD Anderson Canc Ctr, Breast Med Oncol & Clin Canc Genet, Houston, TX USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
98O
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 35 条
  • [1] Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC).
    Abuhadra, Nour
    Sun, Ryan
    Litton, Jennifer Keating
    Rauch, Gaiane M.
    Thompson, Alastair Mark
    Lim, Bora
    Adrada, Beatriz E.
    Mittendorf, Elizabeth A.
    White, Jason B.
    Ravenberg, Elizabeth
    Damodaran, Senthil
    Candelaria, Rosalind P.
    Arun, Banu
    Ueno, Naoto T.
    Santiago, Lumarie
    Murthy, Rashmi Krishna
    Ibrahim, Nuhad K.
    Symmans, William Fraser
    Moulder, Stacy L.
    Huo, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.
    Abuhadra, Nour
    Hess, Kenneth R.
    Litton, Jennifer Keating
    Rauch, Gaiane M.
    Thompson, Alastair Mark
    Lim, Bora
    Adrada, Beatriz E.
    Mittendorf, Elizabeth A.
    Damodaran, Senthil
    Candelaria, Rosalind P.
    Arun, Banu
    Yang, Wei Tse
    Ueno, Naoto T.
    Santiago, Lumarie
    Murthy, Rashmi Krishna
    Ibrahim, Nuhad K.
    Sahin, Aysegul A.
    Symmans, William Fraser
    Moulder, Stacy L.
    Huo, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).
    Miras, Isabel
    Gil, Ana
    Santos-Fernandez, Paloma
    Sanchez-Camacho, Alberto
    Falcon Gonzalez, Alejandro
    Benavent, Marta
    Cejuela Solis, Monica
    Bofill, Salvador
    Flores, Sandra
    Ruiz-Borrego, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Predictive value of tumour infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancer
    Babbar, P. N.
    ANNALS OF ONCOLOGY, 2020, 31 : S1239 - S1239
  • [5] Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.
    Vinayak, Shaveta
    Gray, Robert James
    Adams, Sylvia
    Jensen, Kristin C.
    Manola, Judith
    Afghahi, Anosheh
    Goldstein, Lori J.
    Ford, James M.
    Badve, Sunil S.
    Telli, Melinda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Predictive Value of Tumor-Infiltrating Lymphocytes to Pathological Complete Response in Neoadjuvant Treated Triple-Negative Breast Cancers
    Ruan, Miao
    Tian, Tian
    Rao, Jia
    Xu, Xiaoli
    Yu, Bao-Hua
    Yang, Wentao
    Shui, Ruohong
    LABORATORY INVESTIGATION, 2018, 98 : 102 - 102
  • [7] Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
    Ruan, Miao
    Tian, Tian
    Rao, Jia
    Xu, Xiaoli
    Yu, Baohua
    Yang, Wentao
    Shui, Ruohong
    DIAGNOSTIC PATHOLOGY, 2018, 13
  • [8] Predictive Value of Tumor-Infiltrating Lymphocytes to Pathological Complete Response in Neoadjuvant Treated Triple-Negative Breast Cancers
    Ruan, Miao
    Tian, Tian
    Rao, Jia
    Xu, Xiaoli
    Yu, Bao-Hua
    Yang, Wentao
    Shui, Ruohong
    MODERN PATHOLOGY, 2018, 31 : 102 - 102
  • [9] Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
    Miao Ruan
    Tian Tian
    Jia Rao
    Xiaoli Xu
    Baohua Yu
    Wentao Yang
    Ruohong Shui
    Diagnostic Pathology, 13
  • [10] A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC): Results from the ARTEMIS trial (NCT02276443)
    Seth, Sahil
    Rauch, Gaiane M.
    Adrada, Beatriz
    Piwnica-Worms, Helen
    Hou, Lei
    Thompson, Alastair M.
    Symmans, William F.
    Lim, Bora
    White, Jason
    Draetta, Giulio F.
    Futreal, Andrew
    Chang, Jeffrey
    Moulder, Stacy
    CANCER RESEARCH, 2021, 81 (04)
1234